What is the starting dose of CJC-1295 with DAC?

Most research-planning protocols start at 500-1,000 mcg (0.5-1 mg) once weekly by subcutaneous injection.

What is CJC-1295 with DAC's half-life?

Estimated half-life is approximately 5.8-8.1 days.

What results were reported in CJC-1295 with DAC trials?

Phase 1 data reported growth hormone elevation roughly 2-10 fold and IGF-1 elevation 1.5-3 fold.

How is CJC-1295 with DAC reconstituted?

A 10 mg vial reconstituted with 3.0 mL bacteriostatic water yields about 3,333 mcg/mL.

Is CJC-1295 with DAC FDA-approved?

No, as of June 2026, CJC-1295 with DAC is not FDA-approved.

What are the most common side effects?

Most reported effects include injection-site reactions, flushing, headache, GI symptoms, and water retention.

How does CJC-1295 with DAC compare to CJC-1295 No DAC?

Receptor activity is essentially identical, but DAC extends the half-life to 6-8 days.

What vial sizes are available for CJC-1295 with DAC?

This page's planning math assumes a 10 mg research vial.

Peptidesubcutaneous

CJC-1295 (DAC)

CJC-1295 with DAC is a long-acting GHRH analog peptide that promotes growth hormone release.

Researched for

Recovery

Not yet audited

We have not published an audit on CJC-1295 (DAC). Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.

How it is thought to work

CJC-1295 with DAC binds to circulating albumin, which shields it from breakdown and extends its half-life to about 6-8 days, allowing for sustained signaling to the pituitary gland to release growth hormone. [Source: Peptide Dosing Protocols]

CJC-1295 with DAC is a modified growth hormone-releasing peptide that binds to albumin in the blood, which keeps it active for about 6-8 days per injection, during which it continuously signals the pituitary gland to release growth hormone and raise IGF-1 levels.

Reported side effects

The most commonly reported side effects include injection-site reactions (pain, redness, swelling, lumps), flushing, headache, nausea, water retention, and numbness or tingling, with side effects tending to be more frequent at higher doses and potentially lasting for days due to the long half-life.

Who should avoid it

People with active cancer, significant heart disease, diabetes, those who are pregnant or breastfeeding, anyone with a known peptide allergy, and anyone without qualified medical supervision should avoid CJC-1295 with DAC.

Amount	Frequency	Route	Reported by
Standard: 1,000 mcg once weekly · Low: 500-1,000 mcg once weekly · High: 2,000 mcg once weekly or 1 mg twice weekly	once weekly8-12 weeks · 8-12 weeks on, 4-6 weeks off	Subcutaneous injection	Peptide Dosing Protocols What it saysHide (secondary reference; provider confirmation required). Half-life: 6-8 days. Common research-planning ranges land between 1-2 mg subcutaneously once weekly.
DAC version referenced at 2-3 mg per dose; extended half-life supports infrequent dosing. Bedtime administration cited to align with sleep-phase GH release.	1-2x weekly · Optionally before bedOn-cycle 8-12 weeks, off-cycle 6-12 weeks	subcutaneous	Peptide Therapy Reference Text, internal KB v4 What it saysHide (Aug 2026), secondary reference; provider confirmation required.